Methotrexate is the most common choice for disease-modifying anti-rheumatic drug (DMARD) for rheumatoid arthritis. This prospective study assesses the effect of methotrexate on mortality in a cohort of patients with rheumatoid arthritis.

Some questions to consider while reviewing this article:

• Do you agree with this study design? How would you do things differently?
• Does this study have external validity to our patient population?
• What confounders might have an effect on the results of of methotrexate on mortality in this study?